As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.
Please note that following on from information received from the company this appraisal has now been scheduled back into the work programme.
The appraisal is anticipated to begin during early-March 2023 when we will write to you about how you can get involved.